Because our preliminary studies showed that plasma L59 LAP-DPs tend to be higher in patients suffering from hepatitis than in healthy volunteers, we are now investigating whether plasma L59 LAP-DPs can be used as a fibrogenesis blood marker in patients with chronic active liver disease. The gene discussed is TGFB1; the disease is hepatitis A virus infection.